Umbilical Cord Blood: An Alternate Source of Stem Cells Susan Parker Advisor: David Fahringer PA-C University of Kentucky College of Health Sciences Physician.

Slides:



Advertisements
Similar presentations
Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.
Advertisements

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.
Bone Marrow Transplant in Oncology
Transfusion Post Allogeneic Stem Cell Transplant Robert C. Skeate, MD MS.
Blood and Marrow Transplant: The basics…what you need to know Resident Education Lecture Series.
Hematopoietic Stem Cells A hematopoietic stem cell is a cell isolated from the blood or bone marrow that can renew itself, can differentiate to a variety.
Urszula Jaworska.  Urszula Jaworska was born in February. She was the first Polish patient to receive a bone marrow transplanted from an unrelated donor.
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,
CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.
Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings PowerPoint® Lectures Lectures by Chris Romero, Front Range Community College Whose.
Stem cells Stem cells are ‘generic’ cells that develop into particular types of cells. So they may become nerve cells, muscle cells, blood cells… in fact,
Adult Stem Cell Research What It Can Do and The Church’s Position.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
UMBILICAL CORD STEM CELLS
Shannon N. Barringer, MS Certified Genetic Counselor UAMS Department of OB/GYN ANGELS Program Who Should Bank Their Baby’s Cord Blood?
Building Canada’s National Public Cord Blood Bank.
Cord Blood Donation Its clinical uses and the OB role.
Engineered Cells and Tissues Locksley McGann, PhD Professor Department of Laboratory Medicine and Pathology University of Alberta 24 April, 2012 Analytics,
Asma Sultan Alolama, MD Private Cord Blood Banking Should it be allowed? Asma Sultan Alolama, M.D.
Introduction to Haematopoietic Stem Cell Transplantation (HSCT) Covenant Health System HSCT Program Lubbock, Texas April 4, 2007.
New Approaches for Addressing Long Term Survivorship in Transplant Patients Dennis L. Confer, M.D. Chief Medical Officer National Marrow Donor Program.
 Stem Cells. Definition  The capacity of cells to divide and differentiate along different pathways is necessary in embryonic development. It also makes.
What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.
Cord blood selection, release, and transplantation 6th World Congress Tissue Banking Barcelona, Spain, 10 November 2011 Guillermo Sanz Hospital Universitari.
With the number of people in the United States waiting for a life saving organ transplant growing greater than 100,000 people, the need for organ donors.
STATE HEALTH PLAN REQUEST FOR REVIEW OF DONOR COVERAGE BENEFITS Presented by: S. Elizabeth Sharf August 2015.
Stage 1 Biology Semester Biotechnology
Stem Cells My learning Objectives: 1. What are stem cells? 2. How can stem cells be used to treat medical conditions? 3. What are positives and ethical.
CLONING EVALUATE THERAPEUTIC VS. REPRODUCTIVE. WHAT IS A CLONE? PRECISE GENETIC COPY.
STEM CELLS.  Where do the different cells and tissues in your body come from?  Incredible as it seems, every cell was produced by mitosis from a small.
Text by Leila Marinho Lage An homage to Helen Breder Rio de Janeiro, 22th, August 2006 My ignorance Click to continue.
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
Stem cell research Catholic teaching regarding the stem cell research.
Platelet Transfusions Indications, dose and administration
Bone Marrow Donation Zach Siefker HNRS 1010.
By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.
Bone Marrow Donation. What is Bone marrow?  flexible spongy tissue in the interior of bones such as your hip and thigh.  constitutes 4% of the total.
Bio NOTES: The Biology of Blood The average healthy male has 5 to 6 quarts of blood. The average healthy female has 4 to 5 quarts of blood. Blood takes.
Organ Donation & Transplantation EXCI233 Online source: rs/transplantation/overview_of_transplantation.html?qt.
Safety Review. 2 Sources of Safety Information BLA (Applicant’s data) – : Voluntary questionnaires –2008-present: SCTOD FDA Dockets Literature.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Hematopoietic Stem Cell Current Status and Future Directions
Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.
Cord Blood Presentation to the AZ House Health Committee Charis Ober Save the Cord Foundation January 12, 2016.
Issues in Organ Donation. Organ Transplants  More than 200,000 people in the U.S. suffer from kidney failure.  Treatment of kidney failure generates.
Bone Marrow Transplant
Whose Blood Is It, Anyway?
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
Test – Monday, April 14 Q&A – next lecture Friday, 3 PM, Higgins 300??
Stem Cell doubling is logarithmic
Man & Environment: Biomedical Development
STEM CELLS Mesenchymal precursor cells
Stem Cells.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Stem Cells and Cellular Differentiation
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Timing for HCT Consultation
Cord blood transplantation and stem cell regenerative potential
Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia  Mei-Jie.
Stem cells Stem cells are ‘generic’ cells that develop into particular types of cells. So they may become nerve cells, muscle cells, blood cells… in fact,
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Eliane Gluckman  Experimental Hematology 
Timing for HCT Consultation
Likelihood of finding unrelated donor or cord blood
Likelihood of finding unrelated donor or cord blood
HSCT in children with sickle cell Disease
Presentation transcript:

Umbilical Cord Blood: An Alternate Source of Stem Cells Susan Parker Advisor: David Fahringer PA-C University of Kentucky College of Health Sciences Physician Assistant Program

Objectives w Understand the process of stem cell transplants w Discuss methods of retrieval of stem cells w Learn benefits and disadvantages of using umbilical cord stem cells w Discuss ethical concerns surrounding umbilical cord blood use

Stem Cell Transplants w Stem cell transplants are indicated for hematopoietic malignancies, bone marrow failure syndromes, and genetic immunodifiecient disorders. w When a patient needs a stem cell transplant, a suitable donor must be found. w Immune ablation, to reduce GVHD risk, is administered under intense medical supervision in a sterile environment. w The patient’s recovery begins with an extremely weak and vulnerable immune system with a wide range of complications and opportunistic infection risk.

Stem Cell Transplants (cont’d) w 6 human leukocyte antigens (HLAs) need to be matched between donor and recipient to improve post-transplant prognosis w Only 30% of patients will have the ideal situation: related donor with all six HLA matches w If no suitable related donor, the process of searching the National Marrow Donor Program (NMDP) begins. w Currently, there are two sources of stem cells available to patients, bone marrow derived and umbilical cord derived stem cells.

Your Chances of Finding a Donor w 10 million registered BM donors worldwide w Caucasion has a 50% chance of finding a donor w Minorities are lower, donor programs targeting subpopulations to increase diversity of donor pool. w Basically, <50% chance of finding a donor under any circumstance.

Bone Marrow Stem Cells w Standard stem cell source for over 40 years w Obtained by bone marrow aspiration of the pelvis of donor w Relatively no risk to donor other than pain (no anesthetics used) w From beginning search to actual transplant takes 3-5 months

Umbilical Cord Stem Cells w First successful transplant in 1988 w Relatively low risk to mother and baby w Beginning search to transplant in as few as 21 days

Umbilical Cord Collection w Collected after delivery of baby, before delivery of placenta w Contraindicated in moderate-high risk births w Collected under aseptic techniques and stored at -80  F

Umbilical Cord Retrieval

Benefits of UCSC over BMSC w Decreased transplant time w No chance of donor having acquired disease, infection, nor the possibility of donor declining procedure w Increased diversity of donor pool, much higher rates of minority donation w UCSC have acceptable mortality rates with 4/6 HLA matches w Faster neutrophil engraftment (lower chance of engraftment) w Best prognoses seen in pediatric patients w Non-myeloblative immune destruction has better outcome with UCSC transplant

Drawbacks of UCSC w Longer time to immune system recovery due to immaturity of cells w Leads to increased GVHD and infection risk (but diseases less severe than with BM) w Less effective for adults w Cell dose of one sample usually inadequate for patients with increased body mass w Possible unknown genetic conditions of newborn donor

The Bottom Line w Chance of engraftment similar between BM and UC w Decreased severity of complications with UC w Pooling of two or more UC samples has promising results, ex-vivo expansion of cells being researched w Collecting cord blood has variable results due to technique and delivery complications w Best outcome is still with 6/6 HLA matched related bone marrow donor w UC contains mesenchymal stem cells that have shown promise in becoming various types of tissues: neural, cardiac, hepatic, renal, etc.

Ethics of Using UCSC w Alturistic donation – no cost to donor, increased attention to minorities, LOTS of paperwork and stipulations w Private donation - $ $150/month with no guarantee of successful collection or storage w Recommendations for families with known genetic and inherited disorders w Pressure on families during an already stressful life event w Targeting middle and upper class mothers and obstetricians in wealthy areas w Not available to all women in all areas

Private Cord Banking: Advertisement w

References w Armson, 2005, B. Umbilical Cord Banking: Implications for Perinatal Providers. J Obstet Gynaecol Can March; 27(3): w Ballen, 2005, K. New trends in umbilical cord blood transplantation. Blood May; 105(10): w Barker, 2003, J., Weisdorf, D., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood September; 102(5): w Bieback, 2004, K., Kern, S., Kluter, H., Eichler, H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004; 22: w Fisk, 2005, N., Roberts, I., Markwald, R., Mironov, V. Can Routine Commercial Cord Blood Banking Be Scientifically and Ethically Justified? PloS Medicine February; 2(2): w Laughlin, 2005, M., Giralt, S., Spitzer, T. Umbilical Cord Blood Transplantation: A New Alternative Option. Hematology. 2005; w Lu, L., Yang, S., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with Hematopoiesis-supportive function and other potentials. The Hematology Journ. 2006; 91(8): w O’Brien, 2006, T., Tiedemann, K., Vowels, M. No longer a biological waste product: umbilical cord blood. MJA April; 184(8): w Tuch, 2006, B. Stem Cells: A Clinical Update. Family Physician. 2006; 35: w Wang, 2005, F., Huang, X., Zhang, Y., Chen, Y., Lu, D. Successful transplantation of double unit umbilical-cord blood from unrelated donors in high risk leukemia with a long follow-up. Chinese Medical Journal. 2005; 188(9):